Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.

Topoisomerase 1 (top1) inhibitors are proving useful against a range of refractory tumors, and there is considerable interest in the development of additional top1 agents. Despite crystallographic studies, the binding site and ligand properties that lead to activity are poorly understood. Here we report a unique approach to quantitative structure-activity relationship (QSAR) analysis based on the National Cancer Institute's (NCI) drug databases. In 1990, the NCI established a drug discovery program in which compounds are tested for their ability to inhibit the growth of 60 different human cancer cell lines in culture. More than 70 000 compounds have been screened, and patterns of activity against the 60 cell lines have been found to encode rich information on mechanisms of drug action and drug resistance. Here, we use hierarchical clustering to define antitumor activity patterns in a data set of 167 tested camptothecins (CPTs) in the NCI drug database. The average pairwise Pearson correlation coefficient between activity patterns for the CPT set was 0.70. Coherence between chemical structures and their activity patterns was observed. QSAR studies were carried out using the mean 50% growth inhibitory concentrations (GI(50)) for 60 cell lines as the dependent variables. Different statistical methods, including stepwise linear regression, principal component regression (PCR), partial least-squares regression (PLS), and fully cross-validated genetic function approximation (GFA) were applied to construct quantitative structure-antitumor relationship models. For our data set, the GFA method performed better in terms of correlation coefficients and cross-validation analysis. A number of molecular descriptors were identified as being correlated with antitumor activity. Included were partial atomic charges and three interatomic distances that define the relative spatial dispositions of three significant atoms (the hydroxyl hydrogen of the E-ring, the lactone carbonyl oxygen of the E-ring, and the carbonyl oxygen of the D-ring). The cross-validated r(2) for the final GFA model was 0.783, indicating a predictive QSAR model.

[1]  Jae K. Lee,et al.  Mining and Visualizing Large Anticancer Drug Discovery Databases , 2000, J. Chem. Inf. Comput. Sci..

[2]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[3]  S. Hecht,et al.  Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. , 1999, Biochemistry.

[4]  Y. Pommier,et al.  [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance]. , 1998, Bulletin du cancer.

[5]  Y. Pommier,et al.  Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.

[6]  S. Arbuck,et al.  Clinical applications of the camptothecins. , 1998, Biochimica et biophysica acta.

[7]  J N Weinstein,et al.  Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. , 1998, Journal of medicinal chemistry.

[8]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[9]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[10]  J N Weinstein,et al.  Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. , 1998, Molecular pharmacology.

[11]  M. Ratain,et al.  Topoisomerase I Inhibitors. , 1997, The oncologist.

[12]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[13]  J N Weinstein,et al.  A protein expression database for the molecular pharmacology of cancer , 1997, Electrophoresis.

[14]  Michael R. Boyd,et al.  The NCI In Vitro Anticancer Drug Discovery Screen , 1997 .

[15]  D. Rogers,et al.  Some Theory and Examples of Genetic Function Approximation with Comparison to Evolutionary Techniques , 1996 .

[16]  K. Kohn,et al.  Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. , 1995, Biochemistry.

[17]  M. Wani,et al.  Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. , 1995, Cancer research.

[18]  K. Lackey,et al.  Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. , 1995, Journal of medicinal chemistry.

[19]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[20]  D. Emerson,et al.  In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. , 1995, Cancer research.

[21]  J N Weinstein,et al.  Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. , 1994, Journal of the National Cancer Institute.

[22]  Y. Pommier,et al.  Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. , 1994, The Journal of biological chemistry.

[23]  Anton J. Hopfinger,et al.  Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..

[24]  Y. Pommier,et al.  Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. , 1994, Journal of the National Cancer Institute.

[25]  H. Burris,et al.  Topoisomerase I inhibitors. An overview of the camptothecin analogs. , 1994, Hematology/oncology clinics of North America.

[26]  D Faraggi,et al.  Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action. , 1994, Statistics in medicine.

[27]  M. Grever,et al.  Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS , 1994, Stem cells.

[28]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[29]  W. Goddard,et al.  UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations , 1992 .

[30]  J N Weinstein,et al.  Neural computing in cancer drug development: predicting mechanism of action. , 1992, Science.

[31]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. , 1991, Journal of medicinal chemistry.

[32]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .

[33]  J. Freidman,et al.  Multivariate adaptive regression splines , 1991 .

[34]  L. Liu,et al.  DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. , 1989, Cancer research.

[35]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[36]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[37]  R. Hertzberg,et al.  Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. , 1989, Journal of medicinal chemistry.

[38]  R. D. Iii Cramer,et al.  Comparative Molecular Field Analysis (CoMFA). Part 1. Effect of Shape on Binding of Steroids to Carrier Proteins. , 1988 .

[39]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[40]  Toshio Fujita,et al.  The Correlation of Biological Activity of Plant Growth Regulators and Chloromycetin Derivatives with Hammett Constants and Partition Coefficients , 1963 .